• Paying $12bn for Avidity Biosciences. ($11bn EV)
• Expected to close 1H26.
• Gives access to three late-stage programs for genetic neuromuscular diseases.
• Product launches <2030 so should have a medium-term impact.
• Novartis sees sales growth moving from +5% CAGR to +6%. For 2024-29.
• Conf call today at 1pm CET.
Find more articles and bullets on these widgets:
While we heard the monetary policy views of 6 of 12 current FOMC voters this week, there were no real surprises. We go through all of the relevant FOMC communications in full in our Macro Weekly PDF.
2025 FOMC Voters:
Non-2025 Voters:
We've just published our US Macro Weekly - Download Full Report Here
